

**From:** Smith, Michael (CBER)

**Sent:** Tuesday, August 17, 2021 6:47 PM

**To:** Harkins Tull, Elisa <Elisa.HarkinsTull@pfizer.com>

**Cc:** Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Gottschalk, Laura <Laura.Gottschalk@fda.hhs.gov>; Aghajani Memar, Neda <Neda.AghajaniMemar@pfizer.com>; Devlin, Carmel M <Carmel.Devlin@pfizer.com>

**Subject:** STN 125742.0: IR RE shelf life and date of manufacture

Elisa,

The review team has two questions regarding shelf life and date of manufacture. Please respond as soon as possible and no later than 12:00 PM Wednesday, August 18, 2021.

1. Please send information on what your final, intended drug product shelf life will be and commit to submitting stability data in real time post licensure to support this requested shelf life.
2. Please define your “date of manufacture” for the final, undiluted drug product.

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

**Mike Smith, Ph.D.**  
**Captain, USPHS**

**Senior Regulatory Review Officer**  
**Food and Drug Administration**  
**Center for Biologics Evaluation & Research**  
**Office of Vaccines Research & Review**  
**Division of Vaccines and Related Products Applications**

Tel: 301-796-2640

[michael.smith2@fda.hhs.gov](mailto:michael.smith2@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.